From £6.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

OptiBiotix Health – following recent developments, how does the valuation stack up?

By Tom Winnifrith & Steve Moore | Friday 1 April 2022


Disclosure: I own shares in one or more of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


Shares are now ‘ex-dividend’ for Optibiotix’s ‘ProBiotix Health’ business, which will be spun off onto the AQSE Growth Market – with an associated fundraise – at the end of this month. Additionally, SkinBioTherapeutics (SBTX), in which it has a 20.73% stake, has just announced half-year results – that the market did not like. So, how does the valuation stack up now?

Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

 

PICH

Pitch Pit – this stinks

 

GEX

Georgina Energy: Lyin’ Yet again

Time left: 01:23:10